https://www.selleckchem.com/products/mst-312.html
Trifluridine and tipiracil (FTD/TPI) demonstrated survival benefit vs placebo and manageable safety in previously treated patients with metastatic gastric/gastroesophageal junction cancer (mGC/GEJC) in the randomized, placebo-controlled, phase 3 TAGS study. This subgroup analysis of TAGS examined efficacy/safety outcomes by age. In TAGS, patients with mGC/GEJC and ≥ 2 prior therapies were randomized (21) to receive FTD/TPI 35mg/m or placebo, plus best supportive care. A preplanned subgroup analysis was performed to evaluate efficacy and
Like
Comment
Share
